ReNeuron shares positive data from Phase 1/2a hRPC stem cell study
Category: #health  By Pankaj Singh  Date: 2020-02-25
  • share
  • Twitter
  • Facebook
  • LinkedIn

ReNeuron shares positive data from Phase 1/2a hRPC stem cell study

ReNeuron Group plc, a UK based pharmaceutical firm that specializes in cell-based therapeutics, has recently announced encouraging long-term data from its Phase 1/2a clinical study of hRPC stem cell therapy in RP (retinitis pigmentosa).

Currently, ReNeuron is planning to expand this ongoing trial. Retinitis pigmentosa is basically a group of eye-related hereditary disease that could lead to blindness or progressive loss of sight in patients.

Earlier in October 2019, the company had released encouraging interim efficacy data from the Phase 2a segment’s treated patients of the ongoing Phase 1/2 trial. Moreover, this data was presented at San Francisco’s American Academy of Ophthalmology Meeting by Dr. Pravin Dugel.

Reportedly, the data revealed a cohort of patients who had a positive surgical procedure with constant clinically relevant developments in visual acuity, when assessed against baseline results.

Speaking on the move, Olav Hellebø, Chief Executive Officer, ReNeuron, said that the company is encouraged by these positive data from its Phase 1/2a clinical trial for retinitis pigmentosa patients. Evidently, follow-up data is exceptionally noteworthy in this case, proving that the treatment successfully maintains its favorable effects for at least one year after treatment.

Prior to this news, ReNeuron had made headlines when it announced that its clinical data from the PISCES II Phase 2a clinical study of CTX stem cell treatment for patients suffering from disability after going through stroke, would be published in a peer-reviewed journal.

Sources cite that results from the trial were initially presented at the American Heart Association International Stroke Conference 2018 by Professor Keith Muir in January 2018. Data from this trial can be found online in the Journal of Neurology, Neurosurgery, and Psychiatry (JNNP).

Upon which, CEO Hellebø commented that the company is pleased to see such encouraging data from the PISCES II clinical study of CTX cell therapy being published in a highly regarded peer-reviewed journal.

Source Credit: https://www.prnewswire.com/news-releases/reneuron-announces-positive-long-term-data-in-retinal-clinical-trial-301010085.html



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

US buys all of the global supply of Gilead’s COVID-19 drug remdesivir
US buys all of the global supply of Gilead’s COVID-19 drug remdesivir
By Pankaj Singh

While top-notch companies are racing to develop a vaccine for COVID-19, it looks like the United States has secured almost all of the world’s supply of interim drug remdesivir to treat patients with COVID-19.

...

Potential COVID-19 vaccine by Bharat Biotech to enter clinical trials
Potential COVID-19 vaccine by Bharat Biotech to enter clinical trials
By Pankaj Singh

Bharat Biotech International, a leading Indian biotechnology company, has reportedly announced that its potential coronavirus vaccine, Covaxin, has received Drug Controller General of India (DCGI) approval to start hum...

Seattle Genetics reveals positive data from tisotumab vedotin trial
Seattle Genetics reveals positive data from tisotumab vedotin trial
By Pankaj Singh

Seattle Genetics, Inc., a renowned biotechnology firm that focuses on developing antibody-based cancer treatments, has recently revealed positive topline data from its Phase 2 clinical trial (innovaTV 204) assessing ti...